Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT04308031
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 100 participants
- Sponsor
- Chun-Yao Huang
- Registry
-
NCT04308031
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Taiwan
- Registry status
- Unknown status
Technical summary
Registry record NCT04308031. Randomized; no masking; primary purpose treatment. Start 2018-08-26 (actual); primary completion 2020-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction
- Condition
- Atrial Fibrillation
- Condition
- Ivabradine
- Condition
- Heart Failure
- Intervention (Drug)
- Ivabradine 5 mg [Corlanor]
- Intervention (Drug)
- Digoxin 0.25 mg
- Lead sponsor
- Chun-Yao Huang
Record details
- Record id
cardio:ct-nct04308031- Content hash
d311bab402cd5df2815f05478785645af3776fc3d422c789014ae2ba4406170e